Corrigendum to “Successful kidney-alone transplantation in a patient with PH1 on combination RNA-interference therapy.” Kidney International, 2023;104:203–204
Elisabeth L. Metry(Emma Kinderziekenhuis), Jaap W. Groothoff(University of Amsterdam), Kerensa M. Beekman(Amsterdam Neuroscience), Linda Koster‐Kamphuis(Radboud University Nijmegen), Michiel J.S. Oosterveld(Emma Kinderziekenhuis), Lisa J. Deesker(Emma Kinderziekenhuis), Elisabeth A. M. Cornelissen(Radboud University Medical Center), Sander F. Garrelfs(Emma Kinderziekenhuis)
Cited by 1
Related Papers
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
|New England Journal of Medicine|2021|505
Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment
|Nephrology Dialysis Transplantation|2012|335
Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope
|Nature Reviews Nephrology|2023|154
Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria
|Nephrology Dialysis Transplantation|2011|144